, Volume 184, Issue 1, pp 121–128 | Cite as

Widespread Lichtheimia Infection in a Patient with Extensive Burns: Opportunities for Novel Antifungal Agents

  • Beth K. ThielenEmail author
  • Aaron M. T. Barnes
  • Arick P. Sabin
  • Becky Huebner
  • Susan Nelson
  • Elizabeth Wesenberg
  • Glen T. Hansen
Original Paper


The Mucorales fungi—formerly classified as the zygomycetes—are environmentally ubiquitous fungi, but generally rare causes of clinical infections. In the immunocompromised host, however, they can cause invasive, rapidly spreading infections that confer a high risk of morbidity and mortality, often despite surgical and antifungal therapy. Patients with extensive burn injuries are particularly susceptible to skin and soft-tissue infections with these organisms. Here, we present a case of Lichtheimia infection in a patient with extensive full-thickness burns that required significant and repeated surgical debridement successfully treated with isavuconazole and adjunctive topical amphotericin B washes. We also review the available literature on contemporary antifungal treatment for Lichtheimia species and related Mucorales fungi.


Lichtheimia Isavuconazole Burn Absidia Mucorales 


Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Struck MF, Gille J. Fungal infections in burns: a comprehensive review. Ann Burns Fire Disasters. 2013;26:147–53.Google Scholar
  2. 2.
    Kaur R, Bala K, Ahuja RB, Srivastav P, Bansal U. Primary cutaneous mucormycosis in a patient with burn wounds due to Lichtheimia ramosa. Mycopathologia. 2014;178:291–5.CrossRefGoogle Scholar
  3. 3.
    Muszewska A, Pawłowska J, Krzyściak P. Biology, systematics, and clinical manifestations of zygomycota infections. Eur J Clin Microbiol Infect Dis. 2014;33:1273–87.CrossRefGoogle Scholar
  4. 4.
    Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother. 2016;50:747–57.CrossRefGoogle Scholar
  5. 5.
    Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. 2016;30:143–63.CrossRefGoogle Scholar
  6. 6.
    Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–67. Scholar
  7. 7.
    Mitchell TA, Hardin MO, Murray CK, Ritchie JD, Cancio LC, Renz EM, et al. Mucormycosis attributed mortality: a seven-year review of surgical and medical management. Burns. 2014;40:1689–95. Scholar
  8. 8.
    Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20:5–26.CrossRefGoogle Scholar
  9. 9.
    Ervens J, Ghannoum M, Graf B, Schwartz S. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection. 2014;42:429–32.CrossRefGoogle Scholar
  10. 10.
    Rodriquez Tudela JL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, et al. EUCAST technical note on fluconazole: the European Committee on antimicrobial susceptibility testing—subcommittee on antifungal susceptibility testing (EUCAST-AFST). Clin Microbiol Infect. 2008;14:193–5. Scholar
  11. 11.
    Santos SRCJ, Campos EV, Sanches C, Gomez DS, Ferreira MC. Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients. Clinics. 2010;65:237–43. Accessed 26 June 2018.
  12. 12.
    Hoffmann K, Pawłowska J, Walther G, Wrzosek M, de Hoog GS, Benny GL, et al. The family structure of the Mucorales: A synoptic revision based on comprehensive multigene-genealogies. Persoonia Mol Phylogeny Evol Fungi. 2013;30:57–76.CrossRefGoogle Scholar
  13. 13.
    Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24:247–80.CrossRefGoogle Scholar
  14. 14.
    Garcia-Hermoso D, Dromer F, Alanio A, Lortholary O. Agents of systemic and subcutaneous mucormycosis and entomophthoromycosis. In: Jorgensen JH, Pfaller MA, Carroll KC, Funke G, Landry ML, Richter SS, Warnock DW, editors. Manual of clinical microbiology. 11th ed. American Society of Microbiology; 2016. p. 2087–108.Google Scholar
  15. 15.
    Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13.CrossRefGoogle Scholar
  16. 16.
    Sanguinetti M, Posteraro B. Identification of molds by matrix-assisted laser desorption ionization—time of flight mass spectrometry. J Clin Microbiol. 2017;55:369–79.CrossRefGoogle Scholar
  17. 17.
    Schrödl W, Heydel T, Schwartze VU, Hoffmann K, Große-Herrenthey A, Walther G, et al. Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry. J Clin Microbiol. 2012;50:419–27.CrossRefGoogle Scholar
  18. 18.
    Woo PC, Leung S-Y, Ngan AH, Lau SK, Yuen K-Y. A significant number of reported Absidia corymbifera (Lichtheimia corymbifera) infections are caused by Lichtheimia ramosa (syn. Lichtheimia hongkongensis): an emerging cause of mucormycosis. Emerg Microbes Infect. 2012;1:e15.Google Scholar
  19. 19.
    Ziaee A, Zia M, Bayat M, Hashemi J. Molecular identification of Mucor and Lichtheimia species in pure cultures of Zygomycetes. Jundishapur J Microbiol. 2016;9:e35237.CrossRefGoogle Scholar
  20. 20.
    Bibashi E, De Hoog GS, Pavlidis TE, Symeonidis N, Sakantamis A, Walther G. Wound infection caused by Lichtheimia ramosa due to a car accident. Med Mycol Case Rep. 2013;2:7–10. Scholar
  21. 21.
    Christiaens G, Hayette MP, Jacquemin D, Melin P, Mutsers J, De Mol P. An outbreak of Absidia corymbifera infection associated with bandage contamination in a burns unit. J Hosp Infect. 2005;61:88. Accessed 26 June 2018
  22. 22.
    Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;4:5–24.CrossRefGoogle Scholar
  23. 23.
    Miceli MH, Lee SA. Emerging moulds: epidemiological trends and antifungal resistance. Mycoses. 2011;54:e666–78.CrossRefGoogle Scholar
  24. 24.
    Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17:1855–64.CrossRefGoogle Scholar
  25. 25.
    Lamoth F, Calandra T. Early diagnosis of invasive mould infections and disease. J Antimicrob Chemother. 2017;72:i19–28.CrossRefGoogle Scholar
  26. 26.
    Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016;16:730.CrossRefGoogle Scholar
  27. 27.
    Ingram PR, Suthananthan AE, Rajan R, Pryce TM, Sieunarine K, Gardam DJ, et al. Cutaneous mucormycosis and motor vehicle accidents: findings from an Australian case series. Med Mycol. 2014;52:819–25.CrossRefGoogle Scholar
  28. 28.
    Alastruey-Izquierdo A, Cuesta I, Walther G, Cuenca-Estrella M, Rodriguez-Tudela JL. Antifungal susceptibility profile of human-pathogenic species of Lichtheimia. Antimicrob Agents Chemother. 2010;54:3058–60.CrossRefGoogle Scholar
  29. 29.
    Vitale RG, De Hoog GS, Schwarz P, Dannaoui E, Deng S, Machouart M, et al. Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales. J Clin Microbiol. 2012;50:66–75.CrossRefGoogle Scholar
  30. 30.
    Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. Antimicrob Agents Chemother. 2015;59:7735–42.CrossRefGoogle Scholar
  31. 31.
    Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291–300.CrossRefGoogle Scholar
  32. 32.
    Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61:1558–65.CrossRefGoogle Scholar
  33. 33.
    Pendleton RA, Holmes JH. Systemic absorption of amphotericin B with topical 5% mafenide acetate/amphotericin B solution for grafted burn wounds: Is it clinically relevant? Burns. 2010;36:38–41.CrossRefGoogle Scholar
  34. 34.
    Barsoumian A, Sanchez CJ, Mende K, Tully CC, Beckius ML, Akers KS, et al. In vitro toxicity and activity of Dakin’s solution, mafenide acetate, and amphotericin B on filamentous fungi and human cells. J Orthop Trauma. 2013;27:428–36.CrossRefGoogle Scholar
  35. 35.
    Hussain A, Singh VK, Singh OP, Shafaat K, Kumar S, Ahmad FJ. Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of amphotericin B. Drug Deliv. 2016;7544:1–10.Google Scholar
  36. 36.
    Sosa L, Clares B, Alvarado HL, Bozal N, Domenech O, Calpena AC. Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis. Nanomed Nanotechnol Biol Med. 2017;13:2303–12.CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of Medicine (Division of Infectious Diseases and International Medicine)University of Minnesota School of MedicineMinneapolisUSA
  2. 2.Department of Pediatrics (Division of Pediatric Infectious Diseases and Immunology)University of Minnesota School of MedicineMinneapolisUSA
  3. 3.Department of Laboratory Medicine and PathologyUniversity of Minnesota School of MedicineMinneapolisUSA
  4. 4.Department of Microbiology & ImmunologyUniversity of Minnesota School of MedicineMinneapolisUSA
  5. 5.Department of Pathology & Laboratory MedicineHennepin County Medical CenterMinneapolisUSA

Personalised recommendations